Related Experiment Videos
Management of blood lipid abnormalities in coronary heart disease patients
1Department of Medicine Cardiology, Veterans Administration Hospital, Houston, Texas.
Insights
New strategies for managing dyslipidemia, including medications like colestipol-niacin, gemfibrozil, and lovastatin, are emerging to combat coronary heart disease (CHD). These advancements aim to lower cholesterol and increase protective HDL levels for CHD prevention.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Pharmacology
Background:
- Strong evidence links hyperlipidemia (dyslipidemia) to coronary heart disease (CHD).
- Effective strategies for dyslipidemia control are crucial for CHD prevention.
Purpose of the Study:
- To review recent developments in the management of dyslipidemia.
- To highlight therapeutic approaches for controlling hyperlipidemia and preventing CHD.
Main Methods:
- Review of clinical and laboratory research on dyslipidemia and CHD.
- Discussion of novel therapeutic agents and dietary modifications.
Main Results:
- Colestipol-niacin can control hypercholesterolemia and promote regression of coronary atherosclerosis.
- Gemfibrozil and lovastatin inhibit cholesterol synthesis.
- Gemfibrozil increases levels of high-density lipoprotein (HDL), which protects against atherosclerosis.
Conclusions:
- Emerging treatments offer new avenues for managing dyslipidemia.
- These advancements are expected to stimulate further research in dyslipidemia control.
- Improved dyslipidemia management will facilitate primary and secondary prevention of CHD.
Abstract:
Information obtained from clinical and laboratory research strongly supports a causal relationship between hyperlipidemia (dyslipidemia) and coronary heart disease (CHD), and provides an impetus to develop strategy for control of dyslipidemia. Some recent developments in the field may include the use of: (1) colestipol-niacin to control hypercholesterolemia and induce regression of coronary atherosclerosis; (2) limited amounts of foods rich in stearic or oleic fatty acids to enhance the appeal of cholesterol-lowering regimen; (3) gemfibrozil or lovastatin to inhibit cholesterol synthetic activity; and (4) gemfibrozil to raise atherosclerosis-protective plasma high-density lipoprotein levels. These and other newer developments will stimulate interest in research on dyslipidemia and its control to facilitate primary and secondary prevention of CHD.